Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · vTv Therapeutics Inc. (VTVT)

vTv Therapeutics expands at-the-market share sale program to full amount under ATM

Neutral Impact 2 of 5 financing Written later

On May 13, 2026, vTv Therapeutics filed a prospectus supplement to increase the number of Class A common shares offered under its previously announced at-the-market (ATM) sales program to the full amount provided for under that program. The company also filed a Dechert LLP legal opinion on the legality of the shares issuable under the program, incorporated into its effective Form S-3 shelf registration statement.

Key points

  • Prospectus supplement filed May 13, 2026 raises Class A common stock offered under the ATM Program to the full amount provided for.
  • Dechert LLP legal opinion on the legality of the shares is filed as Exhibit 5.1.
  • The filing does not state the number of shares or the dollar amount involved.

The filing

CompanyvTv Therapeutics Inc. (VTVT)
Form8-K, current report
Filed with the SECMay 13, 2026, 5:20 PM ET
Accession number0001193125-26-221971

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.